Monotherapeutic High-Dose-Rate Brachytherapy for Prostate Cancer: Five-Year Results of an Extreme Hypofractionation Regimen With 54 Gy in Nine Fractions

Yoshioka, Yasuo; Koyama, Koji; Sumida, Iori; Takahashi, Yutaka; Isohashi, Fumiaki; Ogata, Toshiyuki; Koike, Masahiko; Yamazaki, Hideya; Nonomura, Norio; Okuyama, Äkïhïko; Inoue, Takehiro

doi:10.1016/j.ijrobp.2010.02.013

Cited by 102 publications

(51 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yoshioka et al [99] have performed HDR brachytherapy as monotherapy for localized prostate cancer since 1996. The 5-year bRFS rate for low-, intermediate-, and high-risk patients was 85%, 93%, and 79%, respectively.…”

Section: Clinical Results Of Hdr Brachytherapymentioning

confidence: 99%

“…Single higher dose fraction also becomes used for dealing with the issue of needle displacement between each fraction [92]. More recently, several institutes have used HDR brachytherapy as monotherapy without the addition of EBRT, largely for low-risk, but also for intermediate-and highrisk patients [93][94][95][96][97][98][99].…”

Section: Introduction To Hdr Brachytherapymentioning

confidence: 99%

See 1 more Smart Citation

Radiation Therapy for Prostate Cancer

Kariya¹

2013

Advances in Prostate Cancer

View full text Add to dashboard Cite

Section: Clinical Results Of Hdr Brachytherapymentioning

confidence: 99%

Section: Introduction To Hdr Brachytherapymentioning

confidence: 99%

Radiation Therapy for Prostate Cancer

Kariya¹

2013

Advances in Prostate Cancer

View full text Add to dashboard Cite

“…This previous study showed that late Grade 3 GU toxicity was 3.5%, which compared favorably with 3.1% in the present series. Yoshioka et al (18,19) reported that the rate of Grade 2-3 chronic rectal bleeding was ~10% after HDR monotherapy was delivered with a total dose of 54 Gy in nine fractions within 5 days. The GI toxicity of the present two-fraction schedule was minimal, and no Grade 2 or greater GI AEs developed, with the exception of one patient with chronic Grade 2 fecal incontinence.…”

Section: Discussionmentioning

confidence: 99%

Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer

Ashida

Yamasaki

Takagi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the feasibility and preliminary outcomes of high-dose-rate (HDR)-brachytherapy as a monotherapy in two fractions within 1 day for localized prostate cancer, including high-/very high-risk cases. Among the 68 patients treated with HDR monotherapy between July 2011 and December 2014, 65 had a minimal follow-up of 12 months without adjuvant androgen deprivation therapy and were enrolled in the present study [42/65 (64.6%) exhibited high-/very high-risk diseases]. HDR monotherapy was performed in two fractions with a minimal interval of 6 h and the prescribed dose was 13.5 Gy (x2). Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events (version 4;

show abstract

“…В настоящее время имеется порядка 10 достаточно крупных иссле-дований, посвященных оценке результатов лечения больных с помощью ВДБТ в режиме монотерапии. Средний срок наблюдения за пациентами составляет от 2,7 до 8 лет [35][36][37][38][39][40][41]. Наиболее длительные сроки на-блюдения (около 8 лет) провели калифорнийские ис-следователи D. J. Demanes и соавт.…”

Section: особенности проведения различных видов бтunclassified